10 окт. 2023 г. · Lyfnua is a medicine used to treat adults with chronic (long-term) cough which is unexplained or for which other treatments have not worked. The ...

21 июл. 2023 г. · In 2022, gefapixant under the brand name LYFNUA®, was approved in Japan and Switzerland for treatment of adults with refractory or unexplained ...

8 нояб. 2023 г. · The applicant withdrew the marketing authorisation application for Gefzuris (gefapixant) on 14 July 2023. ... EMA product number. EMEA/H/C/005884.

21 дек. 2023 г. · Despite approvals in Europe and Japan, the FDA rejected the oral drug, citing a lack of substantial evidence for treatment effectiveness.

17 нояб. 2023 г. · Gefapixant under the brand name LYFNUA, has been approved in Japan, Switzerland, and the European Union for treatment of adults with ...

21 июл. 2023 г. · In the EU there are no approved therapies for unexplained chronic cough or refractory chronic cough currently. Gefapixant is an orally ...

Marketing approval for gefapixant is being sought in the EU and USA, and the drug was recently approved for marketing in Japan as treatment for refractory or ...

Marketing approval for gefapixant is being sought in the EU and USA, and the drug was recently approved for marketing in Japan as treatment for refractory or ...

It acts as an antagonist of the P2RX3 receptor. ... It was approved for medical use in the European Union in September 2023. Contents.

21 дек. 2023 г. · ... European Medicines Agency (EMA) recommended the approval of gefapixant to treat refractory or unexplained chronic cough. The European ...